Special Issue "Biomarkers for Meningioma"
Deadline for manuscript submissions: closed (30 April 2021).
Interests: Meningioma; biomarker; Neurofibromatosis 2; schwannoma; targeted therapy
Interests: epigenetics; biomarker; glioma; meningioma; master regulator
Meningiomas are the most common primary brain tumours. The current histological classification of meningioma is based on the 2016 WHO recommendations. According to the WHO criteria, meningiomas are classified into 15 histopathological subtypes, which indicate the heterogeneous nature of these tumors. Reflecting their potential clinical course, these subtypes are grouped under WHO grades I through III (benign, intermediate, and malignant subtypes).The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) reformulated the concept of how CNS tumor diagnoses should be structured in the molecular era by adding molecular parameters in addition to histology to define many tumor entities or types (Louis et al. 2016). The change was built on the expansion of knowledge of molecular alterations in tumors and on the growing evidence that integrated histological-molecular features may be superior to a purely histological classification.
In addition, the decision to operate/treat meningiomas is currently based on patients developing new symptoms or showing growth in serial MRI. No blood biomarkers exist currently.
This Special Issue will focus on menigioma biomarkers for prognostic and diagnostic applications and potential relevance for treatment.
Prof. Dr. Oliver Clemens Hanemann
Dr. Houtan Noushmehr
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liquid biopsy
- tissue biomarker